drugset / Trial / NCT06687876
Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy
Phase 2
Recruiting
14 enrolled
Amsterdam UMC, location VUmc
Cancer Center Amsterdam Research Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.
Timeline
- Start
- 2025-03-09
- Primary completion
- 2026-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 500 mg | Oral |